Article Sidebar

PDF
Issue: Vol. 562 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v562i1.18387
Date Published: 10/08/2026
Views 25
Downloads 16
How to Cite
Lê, V. T., Đoàn, S., & Dương, H. K. L. (2026). THE ROLE OF 1,5-ANHYDROGLUCITOL (1,5-AG) IN ASSESSING GLYCEMIC VARIABILITY IN PATIENTS WITH DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Vietnam Medical Journal, 562(1). https://doi.org/10.51298/vmj.v562i1.18387

THE ROLE OF 1,5-ANHYDROGLUCITOL (1,5-AG) IN ASSESSING GLYCEMIC VARIABILITY IN PATIENTS WITH DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Văn Thanh Lê1, Sang Đoàn2, Hà Khánh Linh Dương1,
1 Bệnh viện Chợ Rẫy
2 Bệnh viện Mắt Thành phố Hồ Chí Minh

Main Article Content

Abstract

Background: Hemoglobin A1c (HbA1c) is the standard for monitoring average glycemia, but it misses Glycemic Variability (GV) and Postprandial Hyperglycemia (PPHG)—independent cardiovascular risk factors. 1,5-anhydroglucitol (1,5-AG) is a potential biomarker for short-term (1-2 weeks) glycemic excursions.


Objective: This systematic review synthesizes evidence on the role of 1,5-AG in assessing GV and PPHG in patients with diabetes mellitus (DM).


Methods: We conducted a PRISMA systematic review, searching PubMed, Scopus, and EMBASE for original studies comparing 1,5-AG with GV/PPHG indices. Patients using SGLT2 inhibitors or with severe renal failure (eGFR < 30 mL/min/1.73m2) were excluded.


Results: Fifteen studies (from 745 results) were included in the analysis. Findings showed a strong, consistent inverse correlation between 1,5-AG levels and GV indices (MAGE, r from -0.51 to -0.61) and PPHG indices (MPMG, r ≈ -0.54). 1,5-AG reflected these excursions significantly better than HbA1c (which often showed no correlation). Low 1,5-AG levels were also independently associated with complications (neuropathy, cardiovascular) and increased mortality.


Conclusion: 1,5-AG is a crucial complementary tool to HbA1c, providing valuable information on short-term glycemic control quality (GV and PPHG). It is useful for monitoring early treatment response and identifying patients with good HbA1c but high glycemic excursions.

Keywords

1, 5-Anhydroglucitol (1, 5-AG), Glycemic Variability, Postprandial Hyperglycemia, Diabetes Mellitus, HbA1c

Article Details

References

1. Kim WJ, Park CY. 2013. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine 43(1):33-40.
2. Migala M, Chalubinska-Fendler J, Zielinska M. 2022. 1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular Events. Rev Diabet Stud 18(2):68-75.
3. Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. 2020. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. J Diabetes Res 2020:7489795.
4. Su H, Ni J, Peng D, He X, Lu W, Zhu W, Wang Y, Ma X, Lu J, Zhou J. 2025. Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes. Diabetes Obes Metab 27(9):4772-4781.
5. Swami V, Yadav SK, Saxena P, Sharma A, Dash CK, Gupta A. 2024. Study of Glycemic Variability in Well-controlled Type 2 Diabetic Patients Using Continuous Glucose Monitoring System. J Assoc Physicians India 72(1):18-21.
6. Tanaka K, Sakasai-Sakai A, Motomiya Y, Yoneda T, Takeuchi M. 2021. Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis. Diabetol Metab Syndr 13(1):85.
7. Valente T, Arbex AK. 2021. Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus. Curr Diabetes Rev 17(7):e071620183816.
8. Xu H, Chen R, Hou X, Li N, Han Y, Ji S. 2024. The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus. Front Endocrinol (Lausanne) 15:1471577.